nova bio-pharma product development ltd
nova bio-pharma product development ltd Company Information
Company Number
08153504
Next Accounts
Dec 2025
Shareholders
nova bio-pharma holdings ltd
Group Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
martin house, gloucester crescent, wigston, leicestershire, LE18 4YL
Website
www.novalabs.co.uknova bio-pharma product development ltd Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD at £488.4k based on a Turnover of £374k and 1.31x industry multiple (adjusted for size and gross margin).
nova bio-pharma product development ltd Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD at £0 based on an EBITDA of £-295.8k and a 5.15x industry multiple (adjusted for size and gross margin).
nova bio-pharma product development ltd Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD at £1 based on Net Assets of £1 and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Nova Bio-pharma Product Development Ltd Overview
Nova Bio-pharma Product Development Ltd is a live company located in wigston, LE18 4YL with a Companies House number of 08153504. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2012, it's largest shareholder is nova bio-pharma holdings ltd with a 100% stake. Nova Bio-pharma Product Development Ltd is a established, micro sized company, Pomanda has estimated its turnover at £374k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Nova Bio-pharma Product Development Ltd Health Check
Pomanda's financial health check has awarded Nova Bio-Pharma Product Development Ltd a 1 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 3 areas for improvement. Company Health Check FAQs
0 Strong
3 Regular
3 Weak
Size
annual sales of £374k, make it smaller than the average company (£3.6m)
- Nova Bio-pharma Product Development Ltd
£3.6m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Product Development Ltd
- - Industry AVG
Production
with a gross margin of 54.5%, this company has a comparable cost of product (54.5%)
- Nova Bio-pharma Product Development Ltd
54.5% - Industry AVG
Profitability
an operating margin of -79.1% make it less profitable than the average company (-7.2%)
- Nova Bio-pharma Product Development Ltd
-7.2% - Industry AVG
Employees
with 3 employees, this is below the industry average (46)
3 - Nova Bio-pharma Product Development Ltd
46 - Industry AVG
Pay Structure
on an average salary of £79.3k, the company has an equivalent pay structure (£79.3k)
- Nova Bio-pharma Product Development Ltd
£79.3k - Industry AVG
Efficiency
resulting in sales per employee of £124.7k, this is equally as efficient (£124.7k)
- Nova Bio-pharma Product Development Ltd
£124.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Product Development Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Product Development Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Product Development Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Nova Bio-pharma Product Development Ltd
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Nova Bio-pharma Product Development Ltd
- - Industry AVG
NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD financials
Nova Bio-Pharma Product Development Ltd's latest turnover from March 2024 is estimated at £374 thousand and the company has net assets of £1. According to their latest financial statements, Nova Bio-Pharma Product Development Ltd has 3 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | ||||||||||||
| Gross Profit | ||||||||||||
| Admin Expenses | ||||||||||||
| Operating Profit | ||||||||||||
| Interest Payable | ||||||||||||
| Interest Receivable | ||||||||||||
| Pre-Tax Profit | -1,657,640 | -1,744,443 | -1,912,648 | -595,687 | -299,302 | -628,079 | -245,785 | -129,549 | ||||
| Tax | 662,780 | 541,682 | 386,187 | 200,300 | 139,088 | 182,687 | 37,039 | 20,184 | ||||
| Profit After Tax | -994,860 | -1,202,761 | -1,526,461 | -395,387 | -160,214 | -445,392 | -208,746 | -109,365 | ||||
| Dividends Paid | ||||||||||||
| Retained Profit | -994,860 | -1,202,761 | -1,526,461 | -395,387 | -160,214 | -445,392 | -208,746 | -109,365 | ||||
| Employee Costs | 253,448 | 236,679 | 216,975 | 150,771 | 146,354 | 164,373 | 111,452 | 87,466 | ||||
| Number Of Employees | 3 | 6 | 7 | 6 | 6 | 6 | 6 | 5 | 4 | 9 | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 81,027 | 59,871 | 80,013 | 63,068 | 84,267 | 46,548 | 51,036 | 50,532 | ||||
| Intangible Assets | 1,023,351 | 932,635 | 1,045,678 | 977,953 | 462,944 | 141,664 | ||||||
| Investments & Other | ||||||||||||
| Debtors (Due After 1 year) | 3,670 | 1,596 | 280 | 100 | ||||||||
| Total Fixed Assets | 1,104,378 | 992,506 | 1,125,691 | 1,044,691 | 548,807 | 188,492 | 51,036 | 50,532 | 100 | |||
| Stock & work in progress | ||||||||||||
| Trade Debtors | 2 | 15 | 139 | |||||||||
| Group Debtors | 1 | 4,932,085 | 1,310,145 | 608,658 | 396,931 | 350,488 | 422,297 | 311,106 | ||||
| Misc Debtors | 35,285 | 18,469 | 12,329 | 32,727 | 57,931 | 52,501 | 2,067 | 14 | ||||
| Cash | 104,964 | 83,986 | 145,923 | 245,556 | 94,259 | 152,525 | 165,242 | 186,992 | 2,504 | 1,901 | ||
| misc current assets | ||||||||||||
| total current assets | 1 | 4,932,085 | 1,450,394 | 711,113 | 555,183 | 628,771 | 574,487 | 516,134 | 167,309 | 187,006 | 2,519 | 2,040 |
| total assets | 1 | 4,932,085 | 2,554,772 | 1,703,619 | 1,680,874 | 1,673,462 | 1,123,294 | 704,626 | 218,345 | 237,538 | 2,519 | 2,140 |
| Bank overdraft | ||||||||||||
| Bank loan | ||||||||||||
| Trade Creditors | 1,301 | 12,510 | 8,398 | 23,078 | 39,459 | 24,921 | 84 | 841 | 4,834 | |||
| Group/Directors Accounts | 4,636,291 | 7,266,756 | 5,534,754 | 4,250,769 | 2,797,570 | 1,905,936 | 1,388,627 | 367,277 | 162,779 | |||
| other short term finances | ||||||||||||
| hp & lease commitments | ||||||||||||
| other current liabilities | 197,448 | 97,578 | 152,552 | 176,700 | 106,398 | 84,284 | 148,514 | 187,785 | ||||
| total current liabilities | 4,636,291 | 7,465,505 | 5,644,842 | 4,411,719 | 2,997,348 | 2,051,793 | 1,472,911 | 540,712 | 350,648 | 841 | 4,834 | |
| loans | ||||||||||||
| hp & lease commitments | ||||||||||||
| Accruals and Deferred Income | ||||||||||||
| other liabilities | 6,460 | |||||||||||
| provisions | 137,235 | 111,885 | 119,502 | 526 | 1,037 | |||||||
| total long term liabilities | 137,235 | 111,885 | 119,502 | 526 | 1,037 | 6,460 | ||||||
| total liabilities | 4,636,291 | 7,602,740 | 5,756,727 | 4,531,221 | 2,997,348 | 2,051,793 | 1,472,911 | 541,238 | 351,685 | 7,301 | 4,834 | |
| net assets | 1 | 295,794 | -5,047,968 | -4,053,108 | -2,850,347 | -1,323,886 | -928,499 | -768,285 | -322,893 | -114,147 | -4,782 | -2,694 |
| total shareholders funds | 1 | 295,794 | -5,047,968 | -4,053,108 | -2,850,347 | -1,323,886 | -928,499 | -768,285 | -322,893 | -114,147 | -4,782 | -2,694 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | ||||||||||||
| Depreciation | 22,557 | 25,534 | 20,142 | 34,551 | 30,779 | 15,108 | 12,693 | 4,767 | ||||
| Amortisation | 113,043 | |||||||||||
| Tax | 662,780 | 541,682 | 386,187 | 200,300 | 139,088 | 182,687 | 37,039 | 20,184 | ||||
| Stock | ||||||||||||
| Debtors | -4,932,084 | 3,586,655 | 718,303 | 217,867 | 22,375 | -94,939 | 117,935 | 361,822 | 2,053 | -1 | -224 | 239 |
| Creditors | -1,301 | -11,209 | 4,112 | -14,680 | -16,381 | 39,459 | -24,921 | 24,837 | -757 | -3,993 | 4,834 | |
| Accruals and Deferred Income | -197,448 | 99,870 | -54,974 | -24,148 | 70,302 | 22,114 | -64,230 | -39,271 | 187,785 | |||
| Deferred Taxes & Provisions | -137,235 | 25,350 | -7,617 | 119,502 | -526 | -511 | 1,037 | |||||
| Cash flow from operations | ||||||||||||
| Investing Activities | ||||||||||||
| capital expenditure | ||||||||||||
| Change in Investments | ||||||||||||
| cash flow from investments | ||||||||||||
| Financing Activities | ||||||||||||
| Bank loans | ||||||||||||
| Group/Directors Accounts | -4,636,291 | -2,630,465 | 1,732,002 | 1,283,985 | 1,453,199 | 891,634 | 517,309 | 1,021,350 | 204,498 | 162,779 | ||
| Other Short Term Loans | ||||||||||||
| Long term loans | ||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||
| other long term liabilities | -6,460 | 6,460 | ||||||||||
| share issue | ||||||||||||
| interest | ||||||||||||
| cash flow from financing | 1,732,002 | 1,283,985 | 1,453,199 | 891,634 | 517,309 | 1,021,350 | 204,498 | 156,319 | ||||
| cash and cash equivalents | ||||||||||||
| cash | -104,964 | 20,978 | -61,937 | -99,633 | 151,297 | -58,266 | -12,717 | -21,750 | 184,488 | 603 | 1,901 | |
| overdraft | ||||||||||||
| change in cash | -104,964 | 20,978 | -61,937 | -99,633 | 151,297 | -58,266 | -12,717 | -21,750 | 184,488 | 603 | 1,901 |
nova bio-pharma product development ltd Credit Report and Business Information
Nova Bio-pharma Product Development Ltd Competitor Analysis
Perform a competitor analysis for nova bio-pharma product development ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in LE18 area or any other competitors across 12 key performance metrics.
nova bio-pharma product development ltd Ownership
NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD group structure
Nova Bio-Pharma Product Development Ltd has no subsidiary companies.
Ultimate parent company
1 parent
NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD
08153504
nova bio-pharma product development ltd directors
Nova Bio-Pharma Product Development Ltd currently has 3 directors. The longest serving directors include Dr Peter White (Jul 2012) and Mr Hussain Mulla (Nov 2012).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Peter White | England | 76 years | Jul 2012 | - | Director |
| Mr Hussain Mulla | England | 54 years | Nov 2012 | - | Director |
| Dr James White | England | 39 years | Oct 2020 | - | Director |
P&L
March 2024turnover
374k
-52%
operating profit
-295.8k
0%
gross margin
54.5%
+1.16%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
1
-1%
total assets
1
-1%
cash
0
0%
net assets
Total assets minus all liabilities
nova bio-pharma product development ltd company details
company number
08153504
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
July 2012
age
13
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
March 2024
previous names
nova cra limited (July 2014)
nova 6mp limited (February 2014)
accountant
-
auditor
MOORE
address
martin house, gloucester crescent, wigston, leicestershire, LE18 4YL
Bank
HSBC BANK PLC
Legal Advisor
-
nova bio-pharma product development ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to nova bio-pharma product development ltd. Currently there are 0 open charges and 1 have been satisfied in the past.
nova bio-pharma product development ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NOVA BIO-PHARMA PRODUCT DEVELOPMENT LTD. This can take several minutes, an email will notify you when this has completed.
nova bio-pharma product development ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
